IP Library Patent Application 18982652
Patent Application
App. No. 18/982,652

Artificial Intelligence Detection and Treatment of Biological, Chemical and Radiation Exposure

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/982,652
Abstract

Methods, systems, and compositions of matter for detection, analysis and treatment of biological, chemical and radiation exposure using artificial intelligence-based systems including fuzzy logical and/or machine learning. A system capable of compiling physical, biochemical, hematological, psychological and neural datapoints, analyzing said data points and creating actionable therapeutic interventions in a graded manner based on invasiveness and probability of success. Optimized biological intervention to chemical, radiation and biochemical threats using stem cells, T regulatory cells and induced pluripotent stem cells.

Claims (20)

1 . A method of identifying the potential of developing pathogenic radiological, chemical, or biological reactions using a machine learning system programmed to observe, analyze, and predict based on patient-derived datapoints.

2 . The method of claim 1 , wherein said patient-derived datapoint is perturbation in homeostatic functions.

3 . The method of claim 1 , wherein said patient-derived datapoint is perturbation in immunological functions.

4 . The method of claim 3 , wherein said immunological function alteration is assessed by levels of immune modulatory proteins in one or more biological matrices.

5 . The method of claim 4 , wherein said immune modulatory protein is an aggregation of proteins.

6 . The method of claim 5 , wherein said aggregation of proteins are exosomes.

7 . The method of claim 1 , wherein said detection of potential reactions is accomplished by obtaining a biological fluid and irradiating said fluid, exciting components to emit IR radiation in a wavelength range 8-12 μM; providing a detection system with a detector and analyzer to compare IR radiation patterns with a reference database for identifying threats.

8 . The method of claim 1 , wherein said machine learning system utilizes a knowledge acquisition input platform connected with a database comprising a correlation algorithm to score pathological outcomes based on biological parameters.

9 . The method of claim 8 , wherein elevation of C-reactive protein more than 25% above baseline is utilized to alert need for increased intensity of monitoring.

10 . A method of utilizing one or more artificial intelligence algorithms to suggest therapeutic doses of hematopoiesis-protective therapeutics after exposure to radiation.

11 . The method of claim 10 , wherein historical data is combined with genotypic, phenotypic, and physiological data in respect to the patient being analyzed.

12 . The method of claim 11 , wherein gene polymorphisms for Bcl-2Xs are evaluated and incorporated into said calculation, wherein enhanced Bcl-2Xs is associated with enhanced need for mesenchymal stem cell administration.

13 . The method of claims 12 , wherein said mesenchymal stem cell is derived from a pluripotent stem cell source.

14 . The method of claim 13 , wherein said mesenchymal stem cell is pretreated with one or more agents capable of augmenting expression of interleukin-10.

15 . The method of claim 13 , wherein said agent capable of increasing expression of interleukin-10 is brain-derived neurotrophic growth factor.

16 . A computer-implemented method for identifying risk of biological, chemical, or radiological threats, categorizing potential risks, and providing treatment recommendations through the utilization of an artificial intelligence system.

17 . The method of claim 16 , which creates a score for each of the one or more pathologies, reflecting the likelihood and urgency of treatment needed.

18 . The method of claim 16 , further comprising indicating whether the one or more molecular pathways have synergy in the treatment of the patient.

19 . The method of claim 16 , wherein said molecular pathways include toll-like receptor-associated pathways.

20 . The method of claim 19 , wherein said pluripotency-associated gene is the octamer-binding transcription factor 4 (OCT4).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2026
From: CREATIVE MEDICAL TECHNOLOGIES, INC.
To: BIODEFENSE, INC.
Reel/Frame 073580/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 26, 2024
From: WARBINGTON, TIMOTHY; PATEL, AMIT; ICHIM, THOMAS
To: CREATIVE MEDICAL TECHNOLOGIES, INC.
Reel/Frame 069679/0898 →